250results about How to "Good sustained release" patented technology

An intravaginal drug delivery device comprises a device body comprising a hydrophobic carrier material having at least one channel defining at least one opening to the exterior of said device body, said at least one channel being adapted to receive at least one drug-containing insert; at least one drug-containing insert positioned in said at least one channel, said drug-containing insert capable of releasing a pharmaceutically effective amount of at least one drug suitable for intravaginal administration and containing about 1% to about 70% of at least one water-soluble release enhancer, both the drug and the water-soluble release enhancer dispersed in an insert carrier material; wherein said hydrophobic carrier material and said insert carrier material may be the same or different; and wherein said at least one drug-containing insert is exposed on said exterior of said device body when said intravaginal drug delivery device is in use.

The invention is intended for a treatment of severe infections using an injectable drug-delivery system comprising nanoparticles of a biodegradable polymer with incorporated antibacterial drug.

An apatite-coated solid composition which contains a biodegradable polymer and an apatite-coated solid composition which contains a biodegradable polymer and a medicinal substance have properties of sustained release and of osteoconductive activity.

A method is described for separating, retrieving and concentrating platelets from whole blood relying on aggregation of the platelets followed by filtration. This method eliminates the need of a centrifuge for separating said cells from blood. To obtain cellular concentrates of platelets, blood is mixed with compatible agents that will aggregate cells while retaining contained growth factors. The resulting aggregates can then be separated from blood by filtration. If desired, the filter-captured aggregates are subject to a brief washing cycle where they are washed clean of residual aggregating agent, plasma, and red cells. Aggregates can then be partly or wholly deaggregated and the cells retrieved. The result is a suspension of cells and small aggregates with therapeutic levels of concentrated blood cells with included growth factors that are available for delivery to a wound site. A device that accomplishes the aforementioned process is also described.

This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably α-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.

The present invention is slow released ClO2 air disinfectant, and belongs to the field of hygienic disease controlling and sterilizing technology. The slow released ClO2 air disinfectant consists of ClO2 solution in 1-3 weight portions, silicon gel as the carrier of ClO2 solution in 3 and activator in 0.005-0.1 weight portions. The slow released ClO2 air disinfectant has homogeneous and lasting release to maintain proper ClO2 concentration in the air and reach excellent air disinfecting effect. The used silicon gel may be recovered and reused after treatment.

The invention discloses a swelling-type hollow silk fibroin micro-needle drug delivery system and a preparation method thereof. According to the technical scheme of the preparation method, a swelling modified silk fibroin solution is casted in a PDMS mold to be vacuumized, dried and molded as a hollow needle-type housing. After that, a silk fibroin micro-needle array provided with cavities in the hollow needle-type housing is filled with powder-like or solution-like drugs, vacuumizing and drying are carried out to form a drug part. Finally, a layer of modified silk fibroin solution is cast, dried and molded as a cladded coating. The cladded coating is removed to obtain the swelling-type hollow silk fibroin micro-needle drug delivery system. The drugs are wrapped inside the cavities of the silk fibroin micro-needle arrays, so that the system is high in drug loading ratio and low in skin allergenicity and stimulation. The system facilitates the sustained release and the controlled release of micro-needle drugs. Meanwhile, according to the preparation method, since the swelling modified silk fibroin solution is cast, dried and molded in a mild processing condition, the system is low in processing cost and suitable for large-scale production. Drugs are directly wrapped in the cavities of the swelling hollow micro-needles, so that controlled-release drugs are swelled in the micro-needle base material. In this way, the biological activities of the controlled-release drugs are maintained, while the structure of the hollow silk fibroin micro-needle drug delivery system is greatly simplified. The system is better in practicality.

The invention provides a foam dressing containing a composite silver-zinc antibacterial material and a preparation method of the foam dressing. The foam dressing containing the composite silver-zinc antibacterial material comprises polyurethane foaming plastic and the composite silver-zinc antibacterial material, wherein the composite silver-zinc antibacterial material is adhered to the inside of the polyurethane foaming plastic, comprises the following raw materials in content: nano silver, nano zinc and a nano inorganic carrier; and the composite silver-zinc antibacterial material contains the following raw materials in percentage by mass: 10%-20% of silver and 20%-40% of zinc. The composite silver-zinc antibacterial material is dispersed into the foam dressing in a manner of foam molding or ultrasonic dipping together with foam. The foam dressing containing the composite silver-zinc antibacterial material is capable of effectively absorbing diffusate of the wound surface, and effectively inhibiting growth and breeding of staphylococcus aureus, pseudomonas aeruginosa and candida albicans.

The invention relates to a method for preparing W/O/W type compound emulsion embedding an chlorogenic acid, belonging to the field of compound emulsion preparation and comprising the following steps: mixing 1 part of aqueous chlorogenic acid solution by weight, 2 parts of oil phases by weight and 0.2-0.4 part of lipophilic emulsifier by weight to be stirred for 4-10 minutes under the speed of 6,000-15,000 turns/minute so as to obtain W/O type colostrums; and then mixing 2-3 parts of the W/O type colostrums and 2-3 parts of external water phrases to be stirred for 2-10 minutes under the speed of 1000-6000 turns/minute so as to obtain the W/O/W type compound emulsion. The method for preparing the W/O/W type compound emulsion can not only play roles of protection and storage on the chlorogenic acid, but also realize the uniform and effective release of the chlorogenic acid in human bodies, and also promotes the slow release, the controlled release and the target effect of absorption and sufficiently plays a role of the chlorogenic acid by embedding the hlorogenic acid with the W/O/W type compound emulsion.

The invention discloses a fluid bed tablet-coating machine, which is characterized by the following: possessing dry air inlet and tank of ventilating port; arranging air flow distribution plate and filter in the tank; arranging at least two big hole area on the same angular of even dispersing on the air flow dispersing plate; setting the perforated ratio of the big hole area at 65%; arranging guide barrel on the upper of the air flow dispersing plate; heading on each big hole area; possessing gap between the floor of the guide barrel and the air flow dispersing plate; arranging a dressing injector; corresponding to each guide barrel; projecting the dressing injector from the central hole of the big hole area of the air flow dispersing plate. This invention possesses high output, which can be fit for big scale industrial production.

The invention relates to the treatment of localized pain by providing sustained release of an agent suitable for treating pain, methods for preparing and administering the agent, and methods of formulating and administering the agent as a pharmaceutical preparation. The agent can be locally administered to reduce systemic concentrations of the agent.